PL2698166T3 - Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów - Google Patents

Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów

Info

Publication number
PL2698166T3
PL2698166T3 PL13181901T PL13181901T PL2698166T3 PL 2698166 T3 PL2698166 T3 PL 2698166T3 PL 13181901 T PL13181901 T PL 13181901T PL 13181901 T PL13181901 T PL 13181901T PL 2698166 T3 PL2698166 T3 PL 2698166T3
Authority
PL
Poland
Prior art keywords
nerve regeneration
complement inhibition
improved nerve
improved
complement
Prior art date
Application number
PL13181901T
Other languages
English (en)
Inventor
Frank Baas
Valeria Ramaglia
Original Assignee
Regenesance B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38857887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2698166(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regenesance B V filed Critical Regenesance B V
Publication of PL2698166T3 publication Critical patent/PL2698166T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13181901T 2006-10-10 2007-10-10 Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów PL2698166T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85027706P 2006-10-10 2006-10-10
EP13181901.3A EP2698166B1 (en) 2006-10-10 2007-10-10 Complement inhibition for improved nerve regeneration
EP07834628A EP2073898A1 (en) 2006-10-10 2007-10-10 Complement inhibition for improved nerve regeneration

Publications (1)

Publication Number Publication Date
PL2698166T3 true PL2698166T3 (pl) 2016-03-31

Family

ID=38857887

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15187453T PL3028716T3 (pl) 2006-10-10 2007-10-10 Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
PL13181901T PL2698166T3 (pl) 2006-10-10 2007-10-10 Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15187453T PL3028716T3 (pl) 2006-10-10 2007-10-10 Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów

Country Status (15)

Country Link
US (4) US8703136B2 (pl)
EP (4) EP2073898A1 (pl)
JP (2) JP2010505946A (pl)
AU (1) AU2007307375B2 (pl)
CA (3) CA2666466C (pl)
CY (1) CY1123734T1 (pl)
DK (2) DK2698166T3 (pl)
ES (2) ES2557056T3 (pl)
HU (2) HUE052964T2 (pl)
LT (1) LT3028716T (pl)
NZ (1) NZ576195A (pl)
PL (2) PL3028716T3 (pl)
PT (2) PT3028716T (pl)
SI (2) SI3028716T1 (pl)
WO (1) WO2008044928A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014200822B2 (en) * 2006-10-10 2016-01-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
DK2320925T3 (en) 2008-07-10 2016-03-21 Regenesance B V Komplementantagonister and uses thereof
WO2010022149A1 (en) * 2008-08-20 2010-02-25 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury form intracerebral hemorrhage
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
JP6253578B2 (ja) 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
PL2914291T3 (pl) 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
HUE045646T2 (hu) 2014-06-12 2020-01-28 Ra Pharmaceuticals Inc Komplement aktivitás modulálása
CN107278206B (zh) * 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
PL3280440T3 (pl) 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
EP4218790B1 (en) 2015-12-16 2026-02-18 UCB Holdings, Inc. Modulators of complement activity
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
KR20200095485A (ko) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
LT3893924T (lt) 2018-12-13 2024-10-10 argenx BV Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai
EP3934675A2 (en) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
CA3137895A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors
WO2021231204A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
EP4150085A1 (en) 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
CN115551519A (zh) 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
IL320218A (en) 2022-10-14 2025-06-01 Sanegene Bio Usa Inc Small interfering RNA targeting C3 and its uses
CN120569477A (zh) 2022-12-19 2025-08-29 美国圣因生物股份有限公司 靶向cfb的小干扰rna及其用途

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5177190A (en) 1989-01-03 1993-01-05 Merck & Co., Inc. Purified C5a receptor from human polymorphonuclear leukocytes
EP0497833A1 (en) 1989-10-27 1992-08-12 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis C1 inhibitor muteins and uses thereof
GB9007971D0 (en) 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
DE69429816T2 (de) 1993-09-01 2002-09-19 Stichting Sanquin Bloedvoorziening, Amsterdam C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
SE9503495L (sv) 1995-10-09 1997-04-10 Actinova Ltd Nytt protein
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5922690A (en) 1996-04-25 1999-07-13 Van Gorp; Cornelius L. Dermatan disulfate, an inhibitor of thrombin generation and activation
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
EP1007092B1 (en) 1997-08-26 2006-08-09 Amgen Fremont Inc. A process for inhibiting complement activation via the alternative pathway
DK1047449T3 (da) 1997-10-28 2004-01-26 Univ British Columbia Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US20030096775A1 (en) 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
AU1915100A (en) * 1998-11-17 2000-06-05 Alkermes, Inc. A method of genetic vector delivery
CA2347734A1 (en) 1998-12-15 2000-06-22 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
US6492403B1 (en) 1999-02-09 2002-12-10 3-Dimensional Pharmaceuticals, Inc. Methods of treating C1s-mediated diseases and conditions and compositions thereof
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
AU4095900A (en) 1999-04-28 2000-11-10 University Of British Columbia, The Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
DK1252184T3 (da) 2000-01-31 2008-02-04 Pharming Intellectual Pty Bv Human C1-inhibitor produceret i mælk af transgene dyr
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
JP2004536138A (ja) * 2001-07-26 2004-12-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 認識機能を改善する方法
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
EP1601377A4 (en) 2003-02-21 2009-07-15 Genentech Inc METHOD FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE IN CONNECTION WITH ISCHEMIC REPERFUSION DAMAGE
PT1626736T (pt) 2003-05-16 2020-10-13 Pharming Intellectual Property B V Inibidor c1 com curta meia-vida para tratamento transitório
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005016285A2 (en) * 2003-08-13 2005-02-24 New York University Compositions and methods for inhibiting slit protein and glypican interactions
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
JP2007530454A (ja) 2004-03-26 2007-11-01 プロミックス・ピーティーワイ・リミテッド 補体Ｃ５ａ受容体モジュレーターを使用する神経疾患の治療
NZ551308A (en) 2004-05-14 2009-06-26 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
EP1674580A1 (en) * 2004-12-23 2006-06-28 F. Hoffmann-La Roche Ag Method for identifying activators and/or inhibitors of enzyme activity
WO2006103118A2 (en) 2005-04-01 2006-10-05 Umc Utrecht Holding B.V. Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases
US8911733B2 (en) 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
EP1738763A1 (en) * 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
JP2007008876A (ja) * 2005-06-30 2007-01-18 Avant Immunotherapeutics Inc 脊髄損傷を治療するための補体阻害タンパク質の使用
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
CN102764279B (zh) 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
MX2008004693A (es) 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
SI2380587T1 (en) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury
AU2007224250B2 (en) 2006-03-02 2012-05-03 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CA2655371C (en) 2006-06-15 2017-06-20 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
MX2009010181A (es) 2007-03-22 2009-12-04 Novartis Ag Antigenos c5 y usos de los mismos.
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
US20110008343A1 (en) 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
US20110092446A1 (en) 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
EP2252317B1 (en) 2008-02-15 2014-04-09 Tufts University Treatment of macular degeneration
CA2718588A1 (en) 2008-02-19 2009-08-27 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
WO2009108153A1 (en) 2008-02-29 2009-09-03 The Brigham And Women's Hospital, Inc. Methods and compositions for the regulation of lectin complement pathway (lcp)- associated complement activation in hyperglycemic myocardial damage
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2010022149A1 (en) 2008-08-20 2010-02-25 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury form intracerebral hemorrhage
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2010057084A1 (en) 2008-11-14 2010-05-20 Novelmed Therapeutics, Inc. Method of treating ischemia reperfusion injury
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
CA2791962A1 (en) 2010-03-01 2011-09-09 Alexion Pharmaceuticals, Inc. Methods and compositions for treating degos' disease
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis

Also Published As

Publication number Publication date
HUE026042T2 (en) 2016-05-30
US8703136B2 (en) 2014-04-22
SI2698166T1 (sl) 2016-02-29
HK1225620A1 (en) 2017-09-15
CY1123734T1 (el) 2022-03-24
EP2073898A1 (en) 2009-07-01
AU2007307375B2 (en) 2013-11-28
US20180022824A1 (en) 2018-01-25
DK2698166T3 (en) 2015-12-21
ES2557056T3 (es) 2016-01-21
SI3028716T1 (sl) 2021-01-29
HK1194688A1 (en) 2014-10-24
DK3028716T3 (da) 2020-11-23
AU2007307375A1 (en) 2008-04-17
US20100143344A1 (en) 2010-06-10
ES2831325T3 (es) 2021-06-08
PT3028716T (pt) 2020-11-23
NZ576195A (en) 2012-04-27
PT2698166E (pt) 2016-01-27
CA2666466C (en) 2017-11-14
JP2013189470A (ja) 2013-09-26
WO2008044928A1 (en) 2008-04-17
EP3028716B1 (en) 2020-09-16
CA2980614A1 (en) 2008-04-17
EP2698166A3 (en) 2014-04-02
EP2698166A2 (en) 2014-02-19
EP2698166B1 (en) 2015-09-30
HUE052964T2 (hu) 2021-06-28
LT3028716T (lt) 2020-12-10
CA3154415A1 (en) 2008-04-17
CA2666466A1 (en) 2008-04-17
EP3804755A1 (en) 2021-04-14
EP3028716A1 (en) 2016-06-08
US20140255395A1 (en) 2014-09-11
PL3028716T3 (pl) 2021-03-08
US20220227884A1 (en) 2022-07-21
JP2010505946A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
PT3028716T (pt) Inibição do complemento para regeneração nervosa melhorada
IL257418A (en) Methods for treating addiction
IL198851A0 (en) Methods for treating hypercholesterolemia
EP2079414A4 (en) SYSTEM FOR CHEMOHYPER THERMAL TREATMENT
AP2009004746A0 (en) Process for prepaiIrng diaminophenothiazinium compounds
DK2035004T3 (en) Phenylsubstituerede pyrazinoylguanidin-natriumkanalblokkere med beta-agonistaktivitet
SI2545939T1 (sl) Tetrahidrobiopterin za zdravljenje stanj povezanih s povišanimi nivoji fenilalanina
IL184575A0 (en) Synergistic combinations for treating hypertension
EP2083777A4 (en) RETINAL REGENERATION
PL2487231T3 (pl) Środek do obróbki twardych powierzchni
EP2081437A4 (en) METHODS OF TREATING OR PREVENTING INFESTATION
ZA200810315B (en) Antitumoral dihydropyran-2-one compounds
IL198856A0 (en) Compounds useful for treating neurodegenerative disorders
GB0810364D0 (en) Improved effluent treatment
PL2131841T3 (pl) Sposoby leczenia bólu ostrego
EG26656A (en) Method of regeneration of rubber
GB0600692D0 (en) Well treatment
GB0618168D0 (en) Compounds
KR101881982B1 (ko) 신경 재생제
IL194373A0 (en) Methods for treating kidney disorders
PL2043792T3 (pl) System do obróbki ciągłej
ZA200901672B (en) Compounds for treating proliferative disorders
ZA200903242B (en) Treatment for multiple myeloma
EP2103304A4 (en) COMPOSITION FOR IMPROVING BRAIN FUNCTION
HK1132213A (en) Complement inhibition for improved nerve regeneration